---------------------
OMB APPROVAL
---------------------
OMB Number: 3235-0060
Expires: May 31, 2000
Estimated average
UNITED STATES burden hours per
SECURITIES AND EXCHANGE COMMISSION response 5.00
Washington, D.C. 20549 ---------------------
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) November 2, 2000
--------------------------------
Triangle Pharmaceuticals, Inc.
--------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 000-21589 56-1930728
--------------------------------------------------------------------------------
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
4 University Place, 4611 University Drive, Durham, North Carolina 27707
--------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (919) 493-5980
-----------------------------
--------------------------------------------------------------------------------
(Former name or former address, if changed since last report)
<PAGE>
Item 5. Other Events.
On November 2, 2000, Triangle Pharmaceuticals, Inc. issued a press
release, a copy of which is attached hereto as Exhibit 99.1, and is incorporated
herein by reference.
Item 7. Financial Statements, Pro Forma Financial Information and
Exhibits.
(c) Exhibits. The following documents are filed as exhibits to this
Report:
1.1 Common Stock Underwriting Agreement between the Registrant and
Ramius Securities, LLC dated as of November 1, 2000.
10.1 Stand-by Purchase Agreement between the Registrant and Ramius
Capital Group, LLC dated as of November 1, 2000.
99.1 Press Release, dated November 2, 2000.
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.
Triangle Pharmaceuticals, Inc.
---------------------------------------
(Registrant)
November 3, 2000 /s/ ROBERT F. AMUNDSEN, JR.
------------------------------------- ---------------------------------------
Date (name)
Name: Robert F. Amundsen, Jr.
Title: Executive Vice President and
Chief Financial Officer
